Q: Use of recombinant tissue plasminogen activator (alteplase) in acute ischemic stroke in pregnancy is a (select one)
A) Relative contraindication
B) Absolute contraindication
Alteplase does not cross the placenta but the major concern is various risks associated with hemorrhagic complications in mother and fetus like placental abruption. The American Heart Association/American Stroke Association guidelines designates pregnancy as a relative exclusions. It requires decision on case to case basis taking in confidence all the providers and the family.
1. Murugappan A, Coplin WM, Al-Sadat AN, et al. Thrombolytic therapy of acute ischemic stroke during pregnancy. Neurology 2006; 66:768.
2. Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:630S.
3. Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2016; 47:581.
4. Tassi R, Acampa M, Marotta G, et al. Systemic thrombolysis for stroke in pregnancy. Am J Emerg Med 2013; 31: 448.e1–3